Thrombotic Microangiopathies Clinical Trial
Official title:
Diagnostic and Risk Criteria for Complement Defects in Thrombotic Microangiopathy and Amplifying Conditions, Such as Severe Hypertension: The COMPETE Study.
Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions. Dysregulation of the alternative pathway of complement may be the etiological factor and this type of TMA is classified, according to the current nomenclature, as primary atypical hemolytic uremic syndrome (HUS). Half the patients with primary atypical HUS present with rare variants in complement genes, although coexisting conditions are often needed for the TMA to become manifest. In patients with secondary atypical HUS, certain coexisting conditions appear to drive the disease and treatment should target the underlying condition to remit the TMA. Recently, the investigators demonstrated, by using a novel in-house developed functional endothelial cell-based test, that complement dysregulation and overactivation is the dominant cause of disease and its sequelae in a subset of patients with secondary atypical HUS, having impact on treatment and prognosis. The investigators did first prove this concept in patients presenting with TMA and hypertensive emergency. A prospective study is needed to further corroborate these findings along the spectrum of TMA. The investigators hypothesize that their functional endothelial cell-based test, the so-called "HMEC" test, can better categorizes the TMA into different groups with potential therapeutic and prognostic implications. Thus, paving the road to the ultimate goal of precision medicine.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04098445 -
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
|
||
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Not yet recruiting |
NCT05996679 -
Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study
|
||
Completed |
NCT02222545 -
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
|
Phase 2 | |
Recruiting |
NCT06102694 -
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
|
||
Completed |
NCT03252925 -
A Safety and Efficacy Study of NAC in Patients With TA-TMA
|
Phase 3 | |
Recruiting |
NCT05855083 -
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
|
Phase 2 | |
Completed |
NCT03384693 -
Defibrotide TMA Prophylaxis Pilot Trial
|
Phase 2 | |
Not yet recruiting |
NCT05702996 -
Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies
|
Phase 3 | |
Not yet recruiting |
NCT02373267 -
Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)
|
N/A | |
Recruiting |
NCT06098378 -
Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
|
||
Completed |
NCT02134171 -
Early Predictive Factors of Cardiac and Cerebral Involvement in TMA
|
N/A | |
Not yet recruiting |
NCT06182410 -
Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma
|
Phase 2 | |
Withdrawn |
NCT04970004 -
Study in Adult and Pediatric Patients With HSCT-TMA
|
||
Recruiting |
NCT03205995 -
Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
|
Phase 3 | |
Recruiting |
NCT04784455 -
Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy
|
Phase 3 | |
Active, not recruiting |
NCT04570397 -
Ravulizumab and COVID-19
|
Phase 3 | |
Recruiting |
NCT05634928 -
Construction of a Database for TMA
|
||
Completed |
NCT03518203 -
Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT06291415 -
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
|
Phase 1 |